| Literature DB >> 25957691 |
Marc van de Wetering1, Hayley E Francies2, Joshua M Francis3, Gergana Bounova4, Francesco Iorio5, Apollo Pronk6, Winan van Houdt6, Joost van Gorp7, Amaro Taylor-Weiner8, Lennart Kester9, Anne McLaren-Douglas2, Joyce Blokker1, Sridevi Jaksani1, Sina Bartfeld9, Richard Volckman10, Peter van Sluis10, Vivian S W Li11, Sara Seepo8, Chandra Sekhar Pedamallu3, Kristian Cibulskis8, Scott L Carter3, Aaron McKenna8, Michael S Lawrence8, Lee Lichtenstein8, Chip Stewart8, Jan Koster10, Rogier Versteeg10, Alexander van Oudenaarden9, Julio Saez-Rodriguez5, Robert G J Vries1, Gad Getz3, Lodewyk Wessels4, Michael R Stratton2, Ultan McDermott2, Matthew Meyerson3, Mathew J Garnett12, Hans Clevers13.
Abstract
In Rspondin-based 3D cultures, Lgr5 stem cells from multiple organs form ever-expanding epithelial organoids that retain their tissue identity. We report the establishment of tumor organoid cultures from 20 consecutive colorectal carcinoma (CRC) patients. For most, organoids were also generated from adjacent normal tissue. Organoids closely recapitulate several properties of the original tumor. The spectrum of genetic changes within the "living biobank" agrees well with previous large-scale mutational analyses of CRC. Gene expression analysis indicates that the major CRC molecular subtypes are represented. Tumor organoids are amenable to high-throughput drug screens allowing detection of gene-drug associations. As an example, a single organoid culture was exquisitely sensitive to Wnt secretion (porcupine) inhibitors and carried a mutation in the negative Wnt feedback regulator RNF43, rather than in APC. Organoid technology may fill the gap between cancer genetics and patient trials, complement cell-line- and xenograft-based drug studies, and allow personalized therapy design. PAPERCLIP.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25957691 PMCID: PMC6428276 DOI: 10.1016/j.cell.2015.03.053
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582